Cyfuse Biomedical KK 4892.T · JPY

Its shares trade on Tokyo Stock Exchange under the ticker 4892.T. It has been listed since 1 December 2022. In the fiscal year to 31 December 2025, it reported revenue of ¥231.0m and a net loss of ¥763.8m. At that date it held total assets of ¥4.27bn and shareholders' equity of ¥2.76bn.

Cyfuse Biomedical KK develops and manufactures cell regenerative systems. The company is headquartered in Minato-Ku, Tokyo-To. The company went IPO on 2022-12-01. The firm is engaged in the development of pipelines for obtaining approval for regenerative medicine products and contract research cell products in the field of regenerative medicine. The firm is engaged in the development of cell products as tools for drug discovery support for pharmaceutical companies in the drug discovery support field. The firm is engaged in the development and sell of three-dimensional cell stacking system equipment equipped with basic technology, apply technology for cell product development, and develop new technology in the device field.

Figures and description from our data supplier, not checked against the company's own report.

• Ms. Shizuka AkiedaExecutive President, Chief Executive Officer, Representative Director, since 2016
• Mr. Masahiro SanjoChief Financial Officer, Executive Officer, Director, since 2017
• Mr. Norihiko TokunagaExecutive Officer, Director of System Development, Director, since 2019
• Mr. Kunihiko SuzukiIndependent Director
• Mr. Yasuhiro YoshiokaIndependent Director

Overall

0

Environment

0

Social

0

Governance

0

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.